Certificate of Analysis for NR-52184

Acinetobacter baumannii, Strain MRSN 10372

Catalog No. NR-52184

This reagent is the tangible property of the U.S. Government.

Product Description:

Acinetobacter baumannii (A. baumannii), strain MRSN 10372 was isolated in 2007 from a human urine sample in the United States as part of a global surveillance program. *A. baumannii*, strain MRSN 10372 was deposited as sensitive to amikacin, ampicillin/sulbactam, cefepime, ceftazidime, ciprofloxacin, colistin, imipenem, levofloxacin, meropenem, tetracycline, tobramycin and trimethoprim/sulfamethoxazole and intermediately resistant to gentamicin and ceftriaxone. NR-52184 lot 70042455 was produced by inoculation of the deposited material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70042455 **Manufacturing Date: 24FEB2021**

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: Contact@BEIResources.org. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology	Report results	Circular, convex, entire, smooth and cream (Figure 1)
Growth at 44°C ± 2°C[1] 1 day in an aerobic atmosphere on Tryptic Soy agar	Growth	Growth
Motility Remel™ Motility Test Medium w/TTC Indicator for 1 day at 37°C in an aerobic atmosphere	Report results	Motile
VITEK® MS (MALDI-TOF)	*A. baumannii*	*A. baumannii* (99.9%)
Antibiotic Susceptibility Profile[2,3]		
Amikacin	Sensitive	Sensitive (8 µg/mL)
Ampicillin/sulbactam	Sensitive	Sensitive (1.5 µg/mL)
Cefepime	Sensitive	Sensitive (2 µg/mL)
Ceftriaxone	Intermediate	Intermediate (16 µg/mL)
Ceftazidime	Sensitive	Sensitive (4 µg/mL)
Ciprofloxacin	Sensitive	Sensitive (≤ 0.25 µg/mL)
Colistin	Sensitive	Sensitive (≤ 0.25 µg/mL)
Gentamicin	Intermediate	Sensitive (2 µg/mL)[4]
Imipenem	Sensitive	Sensitive (≤ 1 µg/mL)
Levofloxacin	Sensitive	Sensitive (≤ 1 µg/mL)
Meropenem	Sensitive	Sensitive (≤ 1 µg/mL)
Trimethoprim/sulfamethoxazole	Sensitive	Sensitive (≤ 0.5 µg/mL)
Tobramycin	Sensitive	Sensitive (≤ 1 µg/mL)
Tetracycline	Sensitive	Sensitive (2 to 4 µg/mL)
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene (~ 1470 base pairs)	≥ 99% sequence identity to *A. baumannii*, strain MRSN 10372 (GenBank: VHHM01000032.1)	100% sequence identity to *A. baumannii*, strain MRSN 10372 (GenBank: VHHM01000032.1)

BEI Resources
www.beiresources.org
E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898

Certificate of Analysis for NR-52184

TEST	SPECIFICATIONS	RESULTS
Purity 7 days at 37°C in an aerobic atmosphere with and without 5% CO_2 on Tryptic Soy agar	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology
Viability	Growth	Growth

[1]Growth at 44°C differentiates *A. baumannii* from *A. calcoaceticus and A. pittii*, which do not grow at 44°C.
[2]Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)
[3]Antibiotic susceptibility was tested using a combination of VITEK®2 GN82, Sensititre GNX2F AST and E-test strips.
[4]*A. baumannii*, strain MRSN 10372 was deposited as being intermediately resistant to gentamicin. Repeated antibiotic susceptibility testing determined that for strain MRSN 10372 the gentamicin MIC is 2 µg/mL, which is interpreted as sensitive. Testing was performed in duplicate.

Figure 1: Colony Morphology



/Heather Couch/
Heather Couch 11 JAN 2022
Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

Support Provided by NIAID

BEI Resources
www.beiresources.org
E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898